Certara Launches COVID-19 Pharmacology Online Resource Center
Funded by the Bill & Melinda Gates Foundation, the online Center helps accelerate therapeutics for COVID-19 by integrating clinical pharmacology, innovation and collaboration
Explore Our Scientific Resource Library
Certara’s Simcyp Division Acquires Modeling and Simulation Platform for Neurodegenerative Diseases from In Silico Biosciences, Inc.
PRINCETON, NJ – Feb. 25, 2020 – Certara’s Simcyp Division Acquires Modeling and Simulation Platform for Neurodegenerative Diseases from In Silico Biosciences, Inc. Acquisition will spur the development of new drugs to treat complex neurodegenerative conditions, including Alzheimer’s and Parkinson’s disease.
Arvinas Selects Certara to Advance Speed and Efficiency of its Targeted Protein Degradation Research
PRINCETON, NJ – Feb. 10, 2020 – Arvinas Selects Certara to Advance Speed and Efficiency of its Targeted Protein Degradation Research
Certara Supported 90+ Percent of US FDA Novel New Drug Approvals for Sixth Consecutive Year
PRINCETON, NJ – Jan. 23, 2020 – Certara today reported that more than 90% of novel new drug approvals by the US Food and Drug Administration (FDA) in 2019 were supported by Certara software or services.
Certara Partners with Galderma to Attain FDA Approval of AKLIEF® Topical Acne Cream
PRINCETON, NJ – Jan. 8, 2020 – Certara’s Simcyp® Simulator’s MechDermA™ model provided safety label claim and pediatric dosing information without the need for testing in clinical patients for a topical drug product.
LEO Pharma Joins Certara’s PBPK Simcyp Simulator Consortium
PRINCETON, NJ – Dec. 10, 2019 – LEO Pharma has licensed Certara’s proprietary Simcyp®️ Population-based Simulator and joined its Consortium.
Solution:
PBPK Modeling & Simulation
Certara Announces the Availability of PK Submit, its Pharmacokinetic CDISC Technology Solution
November 21, 2019 PK Submit generates PK CDISC domains automatically, allowing sponsors to file regulatory submissions faster, while also improving data organization and compliance
Certara Scientists to Present Their Latest Modeling and Simulation Advances at 2019 AAPS PharmSci 360
Certara will host two Phoenix WinNonlin™ Lunch and Learns and also lead 18 workshop, presentation and poster sessions on model-informed drug development
Certara Evidence & Access Division to Deliver Innovative Thought Leadership at ISPOR Europe
PRINCETON, NJ – Nov 1, 2019 – Certara thought leaders from its Evidence & Access division will present 12 posters at ISPOR Europe.
Solution:
Evidence and Access
Certara Will Contribute to 26 Model-Informed Drug Development Sessions at ACoP10
Oct 18, 2019 Sessions feature physiologically-based pharmacokinetic (PBPK), pharmacokinetic/pharmacodynamic (PK/PD) and quantitative systems pharmacology (QSP) modeling and simulation
